Determining the Role and Implications of Aurora A Kinase Inhibition In Acute Myeloid Leukemia
PublicDownloadable Content
open in viewerAcute Myeloid Leukemia (AML) is the most common type of blood cancer to occur in adults. AML patients are commonly treated with chemotherapeutic approaches. However, these approaches target pathways common in all proliferating cells, resulting in damaged healthy tissues. Currently, the identification and development of therapies that specifically or preferentially impact growth of leukemia cells is in high demand. Alisertib, an inhibitor of Aurora A kinase, is being investigated clinically as a co-therapeutic for AML. Our studies have focused on exploring the molecular effects of Aurora A inhibition, and investigating cellular biomarkers that may predict drug sensitivity in AML patients. Our results suggest that an increased centriole number confers resistance of AML cells to Alisertib.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Creator
- Publisher
- Identifier
- E-project-032317-122004
- Advisor
- Year
- 2017
- Date created
- 2017-03-23
- Resource type
- Major
- Rights statement
Relations
- In Collection:
Items
Items
Thumbnail | Title | Visibility | Embargo Release Date | Actions |
---|---|---|---|---|
Childers_MQPReportFinal.pdf | Public | Download |
Permanent link to this page: https://digital.wpi.edu/show/6395w876h